<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940222-0-00026</title>
	</head>
	<body>
		<main>
			<p><!-- PJG ITAG l=10 g=1 f=2 --> DATES:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Effective February 22, 1994; written comments, notice of participation, and request for a hearing by March 24, 1994; data, information, and analyses to justify a hearing by April 25, 1994. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> <!-- PJG STAG 4700 -->  <!-- PJG ITAG l=94 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=69 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=50 g=1 f=1 -->   <USDEPT>DEPARTMENT OF HEALTH AND HUMAN SERVICES</USDEPT>  <!-- PJG /ITAG -->  <!-- PJG ITAG l=18 g=1 f=1 -->  <USBUREAU>Food and Drug Administration</USBUREAU> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=1 -->  <CFRNO>21 CFR Parts 442, 444, 448, and 455</CFRNO> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=41 g=1 f=1 -->  <RINDOCK>[Docket No. 93N&hyph;0364]</RINDOCK> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=55 g=1 f=1 --> Antibiotic Drugs; Updates, Technical Changes, and Corrections <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <AGENCY> <!-- PJG ITAG l=10 g=1 f=2 --> AGENCY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Food and Drug Administration, HHS. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </AGENCY> <ACTION> <!-- PJG ITAG l=10 g=1 f=2 --> ACTION:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Final rule. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=59 g=1 f=1 -->  <!-- PJG /ITAG --> </ACTION> <SUMMARY> <!-- PJG ITAG l=10 g=1 f=2 --> SUMMARY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> The Food and Drug Administration (FDA) is amending the antibiotic drug regulations by updating, making noncontroversial technical changes, and making corrections in accepted standards of antibiotic and antibiotic-containing drugs for human use. These changes will result in more accurate and usable regulations. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </SUMMARY> <DATE> <!-- PJG ITAG l=10 g=1 f=2 --> DATES:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Effective February 22, 1994; written comments, notice of participation, and request for a hearing by March 24, 1994; data, information, and analyses to justify a hearing by April 25, 1994. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </DATE> <ADDRESS> <!-- PJG ITAG l=10 g=1 f=2 --> ADDRESSES:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Submit written comments to the Dockets Management Branch (HFA&hyph;305), Food and Drug Administration, rm. 1&hyph;23, 12420 Parklawn Dr., Rockville, MD 20857. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </ADDRESS> <FURTHER> <!-- PJG ITAG l=10 g=1 f=2 --> FOR FURTHER INFORMATION CONTACT:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Peter A. Dionne, Center for Drug Evaluation and Research (HFD&hyph;520), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301&hyph;443&hyph;0335. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </FURTHER> <SUPPLEM> <!-- PJG ITAG l=10 g=1 f=2 --> SUPPLEMENTARY INFORMATION:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> FDA is amending the antibiotic drug regulations by updating, making noncontroversial technical changes, and making corrections in certain antibiotic drug regulations that provide for accepted standards of antibiotic and antibiotic-containing drugs intended for human use. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> In &sect;442.216a(a)(1) (21 CFR 442.216a(a)(1)), separate limits for the pyridine content are being given for the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> L <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> -arginine formulation and the sodium carbonate formulation. Separate limits are needed because the current limits allow the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> L <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> -arginine formulation to contain up to 5.2 milligrams (mg) of pyridine per gram (g) of ceftazidime activity, while the sodium carbonate formulation may not contain more than 4.4 mg of pyridine per g of ceftazidime activity. <!-- PJG 0012 frnewline --> In &sect;442.216a(b)(1)(ii)( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> a <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ), different loss on drying procedures are given for the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> L <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> -arginine formulation and the sodium carbonate formulation. This is necessary because the procedure in the current monograph would not remove all of the water from the sodium carbonate formulation of the product (some water is ``trapped'' as sodium hydrogen carbonate), and the procedure will thus lead to falsely high potency values. Because the two formulations contain differing amounts of ceftazidime pentahydrate as a percent weight by weight of the powder blend, different loss on drying limits are now being given for each formulation. The loss on drying limits are now not more than 12.5 percent if it contains  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> L <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> -arginine and not more than 13.5 percent if it contains sodium carbonate. The asymmetry of the arginine peak is also revised from the current limit of 2.5 to a limit of 4.0. This limit is more realistic of the values obtained in this assay. <!-- PJG 0012 frnewline --> Revisions are being made in the descriptions of certain ophthalmic products (21 CFR part 444) and peptide products (21 CFR part 448). FDA has discovered that some of these monographs contain errors that would allow formulation without preservatives and other essential inactive ingredients to fit the monographs. FDA has not reviewed any of these products without these ingredients and does not know if they are safe and effective. The agency is, therefore, revising certain ophthalmic monographs to correct these errors. <!-- PJG 0012 frnewline --> In &sect;455.185a(a)(1) (21 CFR 455.185a(a)(1)), FDA is making a revision to allow vancomycin hydrochloride for oral solution to contain a suitable stabilizing agent. The agency has reviewed this formulation and found it to be safe and effective. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> Environmental Impact <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> The agency has determined under 21 CFR 25.24(c)(6) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> Submitting Comments and Filing Objections  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> These amendments institute changes that are corrective, editorial, or of a minor technical nature. Because the amendments are not controversial, and because when effective they provide notice of accepted standards, FDA finds that notice, public procedure, and delayed effective date are unnecessary and not in the public interest. This final rule, therefore, becomes effective February 22, 1994. However, interested persons may, on or before March 24, 1994, submit written comments to the Dockets Management Branch (address above). Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday. <!-- PJG 0012 frnewline --> Any person who will be adversely affected by this final rule may file objections to it and request a hearing. Reasonable grounds for the hearing must be shown. Any person who decides to seek a hearing must file (1) on or before March 24, 1994, a written notice of participation and request for a hearing, and (2) on or before April 25, 1994, the data, information, and analyses on which the person relies to justify a hearing, as specified in 21 CFR 314.300. A request for a hearing may not rest upon mere allegations or denials, but must set forth specific facts showing that there is a genuine and substantial issue of fact that requires a hearing. If it conclusively appears from the face of the data, information, and factual analyses in the request for a hearing that no genuine and substantial issue of fact precludes the action taken by this order, or if a request for a hearing is not made in the required format or with the required analyses, the Commissioner of Food and Drugs will enter summary judgment against the person(s) who request(s) the hearing, making findings and conclusions and denying a hearing. All submissions must be filed in three copies, identified with the docket number appearing in the heading of this document and filed with the Dockets Management Branch. <!-- PJG 0012 frnewline --> The procedures and requirements governing this order, a notice of participation and request for a hearing, a submission of data, information, and analyses to justify a hearing, other comments, and grant or denial of a hearing are contained in 21 CFR 314.300. <!-- PJG 0012 frnewline --> All submissions under this order, except for data and information prohibited from public disclosure under 21 U.S.C. 331(j) or 18 U.S.C. 1905, may be seen in the Dockets Management Branch (address above) between 9 a.m. and 4 p.m., Monday through Friday. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> List of Subjects in 21 CFR Parts 442, 444, 448, and 455 <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Antibiotics.  <!-- PJG 0012 frnewline --> Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs, 21 CFR parts 442, 444, 448, and 455 are amended as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=1 --> PART 442_CEPHA ANTIBIOTIC DRUGS <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> 1. The authority citation for 21 CFR part 442 continues to read as follows: <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=4 --> Authority:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> Sec. 507 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 357). <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> 2. Section 442.216a is amended by revising paragraphs (a)(1), (b)(1)(ii)( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> a <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ), and (b)(4) to read as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;442.216a  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Ceftazidime pentahydrate for injection. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (a)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Requirements for certification <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> _(1)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Standards of identity, strength, quality, and purity <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Ceftazidime pentahydrate for injection is a dry mixture of ceftazidime pentahydrate and sodium carbonate or  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> L <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> -arginine. Its ceftazidime potency is satisfactory if each milligram of ceftazidime pentahydrate for injection contains not less than 900 micrograms and not more than 1,050 micrograms of cefazidime activity when corrected for both loss on drying and its sodium carbonate or  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> L <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> -arginine content, as appropriate for the formulation. Its ceftazidime content is satisfactory if it is not less than 90 percent and not more than 120 percent of the number of milligrams of ceftazidime that it is represented to contain. It is sterile. It is nonpyrogenic. Its loss on drying is not more than 12.5 percent if it contains  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> L <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> -arginine and not more than 13.5 percent if it contains sodium carbonate. The pH of its aqueous solution is not less than 5.0 and not more than 7.5. Its pyridine content, if it contains sodium carbonate, is not more than 0.4 percent, except that for the issuance of a certificate for each batch of the sodium carbonate formulation, the pyridine content is not more than 0.12 percent. Its pyridine content, if it contains  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> L <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> -arginine, is not more than 0.3 percent, except that for the issuance of a certificate, the pyridine content of the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> L- <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> arginine formulation is not more than 0.10 percent. The ceftazidime pentahydrate conforms to the standard prescribed by &sect;442.16a(a)(1). <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 --> * * * * * <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (b) *&blank;*&blank;* <!-- PJG 0012 frnewline --> (1) *&blank;*&blank;* <!-- PJG 0012 frnewline --> (ii)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Calculations <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> _( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> a <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> )  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Ceftazidime potency (micrograms per milligram <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ). Calculate the micrograms of ceftazidime per milligram as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <TABLE>  <!-- PJG tableformat 3,L1(0,0,0),b1,tp0,p9,9/1,g1,t1,s20,2,20 -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=95 g=1 f=1 --> &blank; <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1Micrograms of ceftazidime per milligram <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1=  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1 <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=3 --> A <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=5 f=4 --> u <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=1 -->  X  <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=3 --> P <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=5 f=4 --> s <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=1 -->  X 100 <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 2 <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=3 --> A <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=5 f=4 --> s <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=1 -->  X  <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=3 --> C <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=5 f=4 --> u <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=1 -->  X (100- <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=3 --> m <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=1 --> -S-A)  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0152 intable -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=22 g=1 f=1 --> &blank; <!-- PJG /ITAG -->  </TABLE>  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=26 g=1 f=1 --> where:  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=3 --> A <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=5 f=4 --> u <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 -->  = Area of the ceftazidime peak in the chromatogram of the sample (at a retention time equal to that observed for the standard); <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=3 --> A <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=5 f=4 --> s <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 -->  = Area of the ceftazidime peak in the chromatogram of the ceftazidime working standard; <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=3 --> P <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=5 f=4 --> s <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 -->  = Ceftazidime activity in the ceftazidime working standard solution in micrograms per milliliter; <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=3 --> C <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=5 f=4 --> u <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 -->  = Milligrams of sample per milliliter of sample solution; <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=3 --> m <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=5 f=3 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 -->  = Percent loss on drying (determined as directed in &sect;436.200(h) of this chapter if the formulation contains sodium carbonate and determined as directed in &sect;436.200(g) of this chapter if the formulation contains  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=3 --> L <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 --> -arginine); <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> S = Percent sodium carbonate content of the sample (determined as directed in &sect;436.357 of this chapter); and <!-- PJG 0012 frnewline --> A = Percent  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=3 --> L <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> -arginine content of the sample (determined as directed in &sect;455.204 of this chapter, except use ceftazidime instead of aztreonam in the working standard solution and use water instead of mobile phase). Prepare the sample solution by diluting an accurately weighed portion of the contents of a vial with water to 0.2 milligram per milliliter (estimated). The resolution between the ceftazidime peak and the arginine peak is not less than 6.0, the asymmetry factor for the arginine peak is not more than 4.0). <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 --> * * * * * <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (4)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Loss on drying <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Proceed as directed in &sect;436.200(h) of this chapter if the formulation contains sodium carbonate and as directed in &sect;436.200(g) of this chapter if the formulation contains  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> L <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> -arginine. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 --> * * * * * <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=1 --> PART 444_OLIGOSACCHARIDE ANTIBIOTIC DRUGS <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 3. The authority citation for 21 CFR part 444 continues to read as follows: <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=4 --> Authority:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> Sec. 507 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 357). <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> 4. Section 444.320c is amended by revising the second sentence of paragraph (a)(1) to read as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;444.320c  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Gentamicin sulfate-prednisolone acetate ophthalmic suspension.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (a) *&blank;*&blank;* <!-- PJG 0012 frnewline --> (1) *&blank;*&blank;* It contains suitable and harmless chelating agents, tonicity agents, buffers, and preservatives. *&blank;*&blank;* <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 --> * * * * *  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 5. Section 444.342a is amended by revising the first sentence of the undesignated paragraph under paragraph (a)(1)(v) to read as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;444.342a  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Neomycin sulfate- __________ ophthalmic suspension; neomycin sulfate- _____________ ophthalmic solution (the blanks being filled in with the established name(s) of the other active ingredient(s) present in accordance with paragraph (a)(1) of this section). <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (a) *&blank;*&blank;* <!-- PJG 0012 frnewline --> (1) *&blank;*&blank;* <!-- PJG 0012 frnewline --> (v) *&blank;*&blank;*  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> It contains suitable and harmless buffers, dispersants, and preservatives. * * * <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 --> * * * * * <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 6. Section 444.342c is amended by revising the first sentence of the undesignated paragraph under paragraph (a)(1)(ii) to read as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;444.342c  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Neomycin sulfate-gramicidin _____________ ophthalmic solution; neomycin sulfate-gramicidin _________ ophthalmic suspension (the blanks being filled in with the established name(s) of the other active ingredient(s) present in accordance with paragraph (a)(1) of this section). <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (a) *&blank;*&blank;* <!-- PJG 0012 frnewline --> (1) *&blank;*&blank;* <!-- PJG 0012 frnewline --> (ii) *&blank;*&blank;* <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> It contains suitable and harmless buffers, dispersants, irrigants, and preservatives. * * * <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 --> * * * * * <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 7. Section 444.342d is amended by revising the first sentence of the undesignated paragraph under paragraph (a)(1)(iv) to read as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;444.342d  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Neomycin sulfate-polymyxin B sulfate ___________ ophthalmic suspension (the blank being filled in with the established name(s) of the other active ingredient(s) present in accordance with paragraph (a)(1) of this section). <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (a) *&blank;*&blank;* <!-- PJG 0012 frnewline --> (1) *&blank;*&blank;* <!-- PJG 0012 frnewline --> (iv) *&blank;*&blank;*  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> It contains suitable and harmless buffers, dispersants, irrigants, and preservatives. * * * <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 --> * * * * * <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 8. Section 444.342i is amended by revising the second sentence of paragraph (a)(1)(ii) to read as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;444.342i  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Neomycin sulfate-polymyxin B sulfate ophthalmic solution.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (a) *&blank;*&blank;* <!-- PJG 0012 frnewline --> (1) *&blank;*&blank;* <!-- PJG 0012 frnewline --> (ii) *&blank;*&blank;* It contains suitable and harmless buffers, dispersants, irrigants, and <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  preservatives. * * *  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 --> * * * * * <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 9. Section 444.342j is amended by revising the second sentence of paragraph (a)(1) to read as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;444.342j  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Neomycin sulfate-polymyxin B sulfate-dexamethasone ophthalmic suspension. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (a) *&blank;*&blank;* <!-- PJG 0012 frnewline --> (1) *&blank;*&blank;* It contains suitable and harmless buffers, dispersants, irrigants, and <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  preservatives. * * * <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 --> * * * * * <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 10. Section 444.380a is amended by revising the second sentence of paragraph (a)(1) to read as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;444.380a  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Tobramycin ophthalmic solution. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (a) *&blank;*&blank;* <!-- PJG 0012 frnewline --> (1) *&blank;*&blank;* It contains suitable and harmless buffers, dispersants, preservatives, and tonicity agents. * * * <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 --> * * * * * <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 11. Section 444.380c is amended by revising the second sentence of paragraph (a)(1) to read as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;444.380c  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Tobramycin-dexamethasone ophthalmic suspension.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (a) *&blank;*&blank;* <!-- PJG 0012 frnewline --> (1) *&blank;*&blank;* It contains suitable and harmless buffers, dispersants, preservatives, and tonicity agents. * * * <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 --> * * * * * <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=1 --> PART 448_PEPTIDE ANTIBIOTIC DRUGS <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> 12. The authority citation for 21 CFR part 448 continues to read as follows: <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=4 --> Authority:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> Sec. 507 of the Federal Food, Drug, Cosmetic Act (21 U.S.C. 357). <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> 13. Section 448.330 is amended by revising the second sentence of paragraph (a)(1) to read as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;448.330  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Polymyxin B sulfate-trimethoprim hemisulfate ophthalmic solution. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (a) *&blank;*&blank;* <!-- PJG 0012 frnewline --> (1) *&blank;*&blank;* It contains suitable and harmless buffers and preservatives. * * * <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 --> * * * * * <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=1 --> PART 455_CERTAIN OTHER ANTIBIOTIC DRUGS <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> 14. The authority citation for 21 CFR part 455 continues to read as follows: <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=4 --> Authority:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> Sec. 507 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 357). <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> 15. Section 455.185a is amended in paragraph (a)(1) by adding a new sentence after the first sentence to read as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;455.185a  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Vancomycin hydrochloride for oral solution. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (a) *&blank;*&blank;* <!-- PJG 0012 frnewline --> (1) *&blank;*&blank;* It may contain a suitable stabilizing agent. * * * <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 --> * * * * *  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> Dated: February 9, 1994. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SUPPLEM> <SIGNER> <!-- PJG ITAG l=06 g=1 f=1 --> Stephanie R. Gray, <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNER> <SIGNJOB> <!-- PJG ITAG l=04 g=1 f=1 --> Acting Director, Office of Compliance, Center for Biologics Evaluation and Research <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNJOB> <FRFILING> <!-- PJG ITAG l=40 g=1 f=1 --> [FR Doc. 94&hyph;3856 Filed 2&hyph;18&hyph;94; 8:45 am] <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FRFILING> <BILLING> <!-- PJG ITAG l=68 g=1 f=1 --> BILLING CODE 4160&hyph;01&hyph;F <!-- PJG /ITAG --> </BILLING>  <!-- PJG /STAG --></p>
		</main>
</body></html>
            